FAST-PATH is an EU Funded Research Project. Specifically funded by the Marie Curie Industry-Academia Partnerships and Pathways Program.
Home
Prostate Cancer
Prostate cancer is the second most
common form of cancer in men. Approximately 910,000 cases of prostate
cancer were recorded in 2008, accounting for nearly 14% of all new
cancer cases in men. It is predicted that the number of cases will
almost double to 1.7 million by 2030.
FASTPATH Program
The FASTPATH program aims to make a significant difference in our understanding
and treatment of this form of cancer.
A
consortium of industrial and academic partners, it was successfully
awarded a European Marie Curie FP7 grant in November 2011. The grant was
awarded with the purpose of developing high-throughput image analysis
solutions for prostate cancer. The industrial partners, OncoMark Ltd. and
PathXL, are developing and validating novel prostate biomarker imaging
algorithms, tumour identification, quantitative IHC and image search
techniques and subsequently bringing these to the market.
Marie Curie Industry Academia Partnerships and Pathways
The FAST-PATH project is a Marie Curie 'Industry-Academic Pathways and Partnerships' (IAPP) programe which aims to stimulate intersectoral mobility and increase knowledge sharing through joint research partnerships in longer term co-operation programmes between organisations from academia and industry, in particular SMEs and including traditional manufacturing industries.
